ORIC Pharmaceuticals, Inc. (ORIC) |
|
6.13 0.28 (4.79%)
|
01-27 16:00 |
|
Open: |
5.82 |
Pre. Close: |
5.85 |
|
High:
|
6.18 |
Low:
|
5.82 |
|
Volume:
|
145,328 |
Market Cap:
|
269(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:53 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 7.96 One year: 9.3 |
| Support: |
Support1: 4.42 Support2: 2.94 |
| Resistance: |
Resistance1: 6.82 Resistance2: 7.96 |
| Pivot: |
6.03 |
| Moving Average: |
MA(5): 6.14  MA(20): 5.97
MA(100): 3.85 MA(250): 4.5 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 39.9 %D(3): 46.3 |
| RSI: |
RSI(14): 57.9 |
| 52-week: |
High: 9.6 Low: 2.35 |
| Average Vol(K): |
3-Month: 1,019 (K) 10-Days: 338 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORIC ] has closed below upper band by 42.8%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.18 - 6.22 |
6.22 - 6.26 |
|
Low:
|
5.74 - 5.78 |
5.78 - 5.82 |
|
Close:
|
6.06 - 6.13 |
6.13 - 6.19 |
|
Company Description |
|
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. |
Headline News |
Sat, 28 Jan 2023
SCSU Accelerator to assist small businesses - SCNow
Fri, 27 Jan 2023
ORIC Pharmaceuticals, Inc.'s (NASDAQ:ORIC) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance UK
Tue, 24 Jan 2023
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Simply Wall St
Fri, 13 Jan 2023
Regulator demands answers over 'irregularities' in Perth Aboriginal ... - WAtoday
Fri, 13 Jan 2023
Contracts awarded for second phase of Orkney research campus - Insider.co.uk
Fri, 13 Jan 2023
LCWU ORIC ranked 1st among women’s varsities - The News International
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
40 (M) |
| Shares Float |
28 (M) |
|
% Held by Insiders
|
14.9 (%) |
|
% Held by Institutions
|
72.2 (%) |
|
Shares Short
|
2,440 (K) |
|
Shares Short P.Month
|
2,640 (K) |
Stock Financials |
|
EPS
|
-2.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.42 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-19.8 |
|
Return on Equity (ttm)
|
-36 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-76 (M) |
|
Levered Free Cash Flow
|
-42 (M) |
Stock Valuations |
|
PE Ratio
|
-2.78 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.12 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.19 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
